BioCentury | Oct 10, 2011
Finance

Analyst picks & changes

Immunex Corp. Several analysts commented last week on Immunex Corp., in anticipation of the upcoming American Society of Clinical Oncology (ASCO) meeting, which will contain data on Pixykine, IMNX's fusion protein of IL-3 and GM-CSF...
BioCentury | Feb 4, 2008
Product Development

Velcade's true believers

...funding. From its foundation, ProScript had raised $13 million in equity from HealthCare Investment and Dillon Read...
BioCentury | Jun 24, 2002
Finance

Boutique is (again) chic

...the internet. Witness the sales (and many subsequent re-sales) of Robertson Stephens, Hambrecht & Quist, Dillon Read...
BioCentury | Sep 24, 2001
Finance

Ebb & Flow

...million through the sale of 5.5 million shares at $11-$13 through Chase H&Q and Warburg Dillon Read...
BioCentury | Sep 19, 2001
Financial News

NetGenics withdraws IPO

...million through the sale of 5.5 million shares at $11-$13 through Chase H&Q and Warburg Dillon Read...
BioCentury | Oct 12, 2000
Financial News

DrugAbuse withdraws IPO

...Wednesday cut the price again to $8-$9. The deal was to be underwritten by Warburg Dillon Read...
BioCentury | Oct 11, 2000
Financial News

DrugAbuse amends IPO

...$9-$11 on Oct. 6. The deal, which has a 600,000-share overallotment, is underwritten by Warburg Dillon Read...
BioCentury | Oct 3, 2000
Financial News

Ciphergen shoe sold

...million the total raised in the offering, underwritten by SG Cowen; ING Barings; and Warburg Dillon Read...
BioCentury | Sep 29, 2000
Financial News

Ciphergen raises $88 million in IPO

...5.5 million shares at $16 in an IPO. Underwriters SG Cowen, ING Barings and Warburg Dillon Read...
BioCentury | Sep 1, 2000
Financial News

Aclara announces early release of lock-up

...days following the original lock-up expiration date on Sept. 16. Deutsche Banc Alex. Brown; Warburg Dillon Read...
Items per page:
1 - 10 of 173
BioCentury | Oct 10, 2011
Finance

Analyst picks & changes

Immunex Corp. Several analysts commented last week on Immunex Corp., in anticipation of the upcoming American Society of Clinical Oncology (ASCO) meeting, which will contain data on Pixykine, IMNX's fusion protein of IL-3 and GM-CSF...
BioCentury | Feb 4, 2008
Product Development

Velcade's true believers

...funding. From its foundation, ProScript had raised $13 million in equity from HealthCare Investment and Dillon Read...
BioCentury | Jun 24, 2002
Finance

Boutique is (again) chic

...the internet. Witness the sales (and many subsequent re-sales) of Robertson Stephens, Hambrecht & Quist, Dillon Read...
BioCentury | Sep 24, 2001
Finance

Ebb & Flow

...million through the sale of 5.5 million shares at $11-$13 through Chase H&Q and Warburg Dillon Read...
BioCentury | Sep 19, 2001
Financial News

NetGenics withdraws IPO

...million through the sale of 5.5 million shares at $11-$13 through Chase H&Q and Warburg Dillon Read...
BioCentury | Oct 12, 2000
Financial News

DrugAbuse withdraws IPO

...Wednesday cut the price again to $8-$9. The deal was to be underwritten by Warburg Dillon Read...
BioCentury | Oct 11, 2000
Financial News

DrugAbuse amends IPO

...$9-$11 on Oct. 6. The deal, which has a 600,000-share overallotment, is underwritten by Warburg Dillon Read...
BioCentury | Oct 3, 2000
Financial News

Ciphergen shoe sold

...million the total raised in the offering, underwritten by SG Cowen; ING Barings; and Warburg Dillon Read...
BioCentury | Sep 29, 2000
Financial News

Ciphergen raises $88 million in IPO

...5.5 million shares at $16 in an IPO. Underwriters SG Cowen, ING Barings and Warburg Dillon Read...
BioCentury | Sep 1, 2000
Financial News

Aclara announces early release of lock-up

...days following the original lock-up expiration date on Sept. 16. Deutsche Banc Alex. Brown; Warburg Dillon Read...
Items per page:
1 - 10 of 173